
    
      To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as
      determined by a 50% improvement of an American College of Rheumatology criteria (ACR50)
      response at Week 14 (Stage A of study).

      Stage B of this trial is Double blind.
    
  